These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The role of epithelial-mesenchymal transition drivers ZEB1 and ZEB2 in mediating docetaxel-resistant prostate cancer. Hanrahan K; O'Neill A; Prencipe M; Bugler J; Murphy L; Fabre A; Puhr M; Culig Z; Murphy K; Watson RW Mol Oncol; 2017 Mar; 11(3):251-265. PubMed ID: 28133913 [TBL] [Abstract][Full Text] [Related]
5. Double-negative feedback loop between ZEB2 and miR-145 regulates epithelial-mesenchymal transition and stem cell properties in prostate cancer cells. Ren D; Wang M; Guo W; Huang S; Wang Z; Zhao X; Du H; Song L; Peng X Cell Tissue Res; 2014 Dec; 358(3):763-78. PubMed ID: 25296715 [TBL] [Abstract][Full Text] [Related]
6. Genetic interaction between Tmprss2-ERG gene fusion and Nkx3.1-loss does not enhance prostate tumorigenesis in mouse models. Linn DE; Bronson RT; Li Z PLoS One; 2015; 10(3):e0120628. PubMed ID: 25780911 [TBL] [Abstract][Full Text] [Related]
7. TMPRSS2:ERG gene fusion variants induce TGF-β signaling and epithelial to mesenchymal transition in human prostate cancer cells. Ratz L; Laible M; Kacprzyk LA; Wittig-Blaich SM; Tolstov Y; Duensing S; Altevogt P; Klauck SM; Sültmann H Oncotarget; 2017 Apr; 8(15):25115-25130. PubMed ID: 28445989 [TBL] [Abstract][Full Text] [Related]
8. Loss of the polycomb protein Mel-18 enhances the epithelial-mesenchymal transition by ZEB1 and ZEB2 expression through the downregulation of miR-205 in breast cancer. Lee JY; Park MK; Park JH; Lee HJ; Shin DH; Kang Y; Lee CH; Kong G Oncogene; 2014 Mar; 33(10):1325-35. PubMed ID: 23474752 [TBL] [Abstract][Full Text] [Related]
9. TFAP2A is a component of the ZEB1/2 network that regulates TGFB1-induced epithelial to mesenchymal transition. Dimitrova Y; Gruber AJ; Mittal N; Ghosh S; Dimitriades B; Mathow D; Grandy WA; Christofori G; Zavolan M Biol Direct; 2017 Apr; 12(1):8. PubMed ID: 28412966 [TBL] [Abstract][Full Text] [Related]
10. Integrin-linked kinase as a target for ERG-mediated invasive properties in prostate cancer models. Becker-Santos DD; Guo Y; Ghaffari M; Vickers ED; Lehman M; Altamirano-Dimas M; Oloumi A; Furukawa J; Sharma M; Wang Y; Dedhar S; Cox ME Carcinogenesis; 2012 Dec; 33(12):2558-67. PubMed ID: 23027626 [TBL] [Abstract][Full Text] [Related]
11. Loss of the NKX3.1 tumorsuppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer. Thangapazham R; Saenz F; Katta S; Mohamed AA; Tan SH; Petrovics G; Srivastava S; Dobi A BMC Cancer; 2014 Jan; 14():16. PubMed ID: 24418414 [TBL] [Abstract][Full Text] [Related]
12. UBE2C, Directly Targeted by miR-548e-5p, Increases the Cellular Growth and Invasive Abilities of Cancer Cells Interacting with the EMT Marker Protein Zinc Finger E-box Binding Homeobox 1/2 in NSCLC. Jin D; Guo J; Wu Y; Du J; Wang X; An J; Hu B; Kong L; Di W; Wang W Theranostics; 2019; 9(7):2036-2055. PubMed ID: 31037155 [No Abstract] [Full Text] [Related]
13. Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Graham TR; Zhau HE; Odero-Marah VA; Osunkoya AO; Kimbro KS; Tighiouart M; Liu T; Simons JW; O'Regan RM Cancer Res; 2008 Apr; 68(7):2479-88. PubMed ID: 18381457 [TBL] [Abstract][Full Text] [Related]
14. miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells. Kong D; Li Y; Wang Z; Banerjee S; Ahmad A; Kim HR; Sarkar FH Stem Cells; 2009 Aug; 27(8):1712-21. PubMed ID: 19544444 [TBL] [Abstract][Full Text] [Related]
15. [The progress of TMPRSS2-ETS gene fusions and their mechanism in prostate cancer]. Guo XQ; Gui YT; Cai ZM Yi Chuan; 2011 Feb; 33(2):117-22. PubMed ID: 21377967 [TBL] [Abstract][Full Text] [Related]
16. miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT. Kao CJ; Martiniez A; Shi XB; Yang J; Evans CP; Dobi A; deVere White RW; Kung HJ Oncogene; 2014 May; 33(19):2495-503. PubMed ID: 23728339 [TBL] [Abstract][Full Text] [Related]
17. Morphological features of TMPRSS2-ERG gene fusion prostate cancer. Mosquera JM; Perner S; Demichelis F; Kim R; Hofer MD; Mertz KD; Paris PL; Simko J; Collins C; Bismar TA; Chinnaiyan AM; Rubin MA J Pathol; 2007 May; 212(1):91-101. PubMed ID: 17385188 [TBL] [Abstract][Full Text] [Related]
18. TMPRSS2- driven ERG expression in vivo increases self-renewal and maintains expression in a castration resistant subpopulation. Casey OM; Fang L; Hynes PG; Abou-Kheir WG; Martin PL; Tillman HS; Petrovics G; Awwad HO; Ward Y; Lake R; Zhang L; Kelly K PLoS One; 2012; 7(7):e41668. PubMed ID: 22860005 [TBL] [Abstract][Full Text] [Related]
19. TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer. Swanson TA; Krueger SA; Galoforo S; Thibodeau BJ; Martinez AA; Wilson GD; Marples B Prostate; 2011 Oct; 71(14):1548-58. PubMed ID: 21394739 [TBL] [Abstract][Full Text] [Related]